Condition
Dystrophinopathy
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 3 (1)
Trial Status
Recruiting2
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07609394Recruiting
Duchenne Electronic Health Record Study
NCT07580365Not ApplicableNot Yet RecruitingPrimary
VirtualPark_Pediatric
NCT02069756Recruiting
The Duchenne Registry
NCT01557400Phase 3Completed
Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada
NCT01388764Phase 1CompletedPrimary
Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids
Showing all 5 trials